SABCS 2021
Good data with further questions for future treatment in a neoadjuvant setting
KEYNOTE-522
SABCS 2021
Good data with further questions for future treatment…
KEYRICHED-1
SABCS 2021
Hypothesis-generating study in the HER2-enriched…
Keynote-522
SABCS 2021
The next standard for TNBC?!
CCtGMA.32 (Metformin)
SABCS 2021
Metformin is not an anti-cancer drug
cTRAK TN
SABCS 2021
Leading the way for other ct-DNA trials
RxPONDER
SABCS 2021
Benefit only related to chemotherapy?!
BRE12-158
SABCS 2021
Molecular-guided treatment is of value in combination…
Breast Pre-Cancer Atlas
SABCS 2021
Genomic signatures of DCIS
RXPONDER
SABCS 2021
Critical consideration of the study data is necessary
TEXT, SOFT
SABCS 2021
The risk-adapted decision for or against AI has to be…
PALLAS
SABCS 2021
Negative results with hope for translational projects
KeyNOTE-522
SABCS 2021
Re-evaluation confirms old data
CCtG MA.32 (Metformin)
SABCS 2021
Metformin shows no efficacy for most cancer patients
RXPonder; CCtGMA.32 (Metformin)
SABCS 2021
Solved and unsolved controversies of early breast…
Bre12-158
SABCS 2021
Genomisch gesteuererte Therapie sinnvoll in Kombi mit…
KEYRICHED-1
SABCS 2021
Hypothesen-generierende Studie beim HER2-enriched…
RxPONDER
SABCS 2021
E’ solo effetto della chemioterapia?
Breast Pre-Cancer Atlas
SABCS 2021
"Signatures Genomiche " nel carcinoma duttale in situ
RXPONDER
SABCS 2021
Kritische Betrachtung der Studiendaten notwendig
TEXT, SOFT
SABCS 2021
Muss die risiko-adaptierte Entscheidungsfindung bei AI…
KeyNOTE-522
SABCS 2021
Erneute Auswertung bestätigt alte Daten
PALLAS
SABCS 2021
Negative Ergebnisse, aber Hoffnung für translationale…
CCtGMA.32 (Metformin)
SABCS 2021
La metformina non può essere considerata un farmaco…
cTRAK TN
SABCS 2021
cTRAK TN: ctDNA monitoring not yet ready for primetime.…
Keynote-522; OlympiA
SABCS 2021
KEYNOTE-522 confirms ICI benefit in the neoadjuvant…
RxPONDER
SABCS 2021
RxPONDER: Benefit only for pre-menopausal patients?…
SABCS 2021
MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of…
PALLAS; PENELOPE-B
SABCS 2021
HR+ EBC: What about PALLAS/PENELOPE-B? What is the…
Destiny-Breast 03; DAISY; SUMMIT
SABCS 2021
HER2+ EBC: Chemotherapy free regimens? Extended…
Keynote-522
SABCS 2021
TNBC EBC: What is the new neoadjuvant standard…
SAFIR02-Breast
SABCS 2021
Precision oncology is beneficial in certain mBC…
Destiny-Breast03; DAISY
SABCS 2021
More good news for TDXd
Tropion-PanTumor01
SABCS 2021
Promising results for TNBC patients
Keynote-355; Tropion-PanTumor01
SABCS 2021
Exciting novel therapies for metastatic TNBC
Destiny-Breast03; DAISY
SABCS 2021
Reconfirming effect of T-DXd in patients with brain…
Pada-1
SABCS 2021
Switching with molecular progress improves PFS
MONALEESA 2, 3, 7
SABCS 2021
Pooled analyses shows OS benefit for most subgroups
SABCS 2021
Amazing period for patients with refractory metastatic…
Keynote-522 Keynote-355 Destiny-Breast03
SABCS 2021
3 updates - 3 new standards of care
EMERALD
SABCS 2021
Oral SERDs are efficient, but show high progression…
Destiny-Breast03
SABCS 2021
T-Dxd is also active in patients with brain metastasis
MSK IMPACT
SABCS 2021
Patients with BRCA2 don't show PFS benefit with CDK4/6i
TROPION-PanTumor01; ASCENT
SABCS 2021
TROP2 - new target for improved chemotherapy
KeyNOTE-355
SABCS 2021
Effectiveness depending on PDL1 status
SABCS 2021
My highlights of 2021 in metastatic breast cancer
SAFIR02-Breast
SABCS 2021
Pioneering study of personalized medicine in advanced…
KeyNOTE-522
SABCS 2021
Robust benefit of pembroluzimab in addition to…
DAISY
SABCS 2021
Activity of T-Dxd across all Her2-expressing breast…
EMERALD
SABCS 2021
Elacestrant - less than we expected
EMERALD
SABCS 2021
Oral SERDs for early setting and adjuvant therapy
Tropion-PanTumor01
SABCS 2021
Dato-DXd new promising ADC
EMERALD
SABCS 2021
Very good news for endocrine resistant metastatic…
Pada-1
SABCS 2021
PFS improvement with fulvestrant in patients with…
Samuraciclib Phase I
SABCS 2021
Samuraciclib - new targeted therapy for luminal breast…
NIMBUS
SABCS 2021
Immuntherapy for high tumor mutation burden in…
Tropion-PanTumor01
SBCS 2021
Dato-Dxd for metastatic TNBC
SABCS 2021
Best of the year: systemic therapy
DESTINY Breast-03
SABCS 2021
TDXd is very efficient in patients with brain…
Nimbus
SABCS 2021
IO + IO without resounding success in the mBC setting
Keynote-355
SABCS 2021
Final results of the CPS score subgroup analyses show…
Nimbus; Keynote-355
SABCS 2021
Chekpoint inhibition in breast cancer
KEYNOT-355
SABCS 2021
Which patients will benefit from Pembro in metastatic…
NeoTRIPaPDL1
ASH 2021
Imaging with mass cytometry can provide predictive…
SABCS 2021
Mi retrospectiva del cáncer de mama metastático en 2021
Tropion-PanTumor01
SABCS 2021
Dato-DXd – nowy obiecujący koniugat przeciwciała i…
Pada-1
SABCS 2021
Amélioration de la survie sans progression par le…
KeyNOTE-355
SABCS 2021
Wirksamkeit in Abhängigkeit von PDL1-Stautus
Nimbus; Keynote-355
SABCS 2021
Checkpoint-Inhibition beim Mammakarzinom
MSK Impact
SABCS 2021
HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil…
Tropion-PanTumor01
SABCS 2021
Résultats prometteurs dans le cancer du sein triple…
PADA-1
SABCS 2021
Umstellung bei molekularem Progress verlängert PFS
Tropion-PanTumor01
SABCS 2021
Risultati promettenti nel tumore al seno triplo…
Monaleesa 2, 3, 7
SABCS 2021
Gepoolte Analyse zeigt OS Vorteil für fast alle…
SABCS 2021
Best of the Year: Systemtherapie
Destiny-Breast03
SABCS 2021
Activité du T-DXd dans les metastases cérébrales
Safir02-Breast
SABCS 2021
Wegweisende Daten für die personalisierte Medizin beim…
Emerald
SABCS 2021
Buone notizie per i tumori mammari endocrino resistenti
Keynote-522
SABCS 2021
Important benefice de l’ajout du pembrolizumab à la…
Destiny-Breast03
SABCS 2021
T-Dxd aktywny również w przerzutach do mózgu
Samuraciclib Phase I
SABCS 2021
Samuracyklib – nowe leczenie celowane w rakach…
Emerald
SABCS 2021
Oraler Serd wirkt, aber hohe Rate an primärer Resistenz
NeoTRIPaPDL1
SABCS 2021
L’imaging mass cytometry può aiutare a predire…
Tropion-PanTumor01; Ascent
SABCS 2021
Neues Target für optimierte Chemotherapie
Keynote-355
SABCS 2021
Resultados finales de los análisis de los subgrupos de…
Emerald
SABCS 2021
Werden orale SERDs die Therapie mit Fulvestrant in…
Emerald
SABCS 2021
Elacestrant – poniżej oczekiwań
Tropion-PanTumor01
SABCS 2021
È un grande momento per i pazienti con tumore mammario…
SAFIR02-BREAST
SABCS 2021
Präzisionsonkologie funktioniert beim mBC
Nimbus
SABCS 2021
IO + IO ohne durchschlagenden Erfolg beim mBC
Destiny-Breast-03
SABCS 2021
TDXd zeigt große Wirksamkeit bei Hirnmetastasen
SABCS 2021
MBC HER2+: How can we manage the metastatic disease and…
SABCS 2021
MBC TNBC: Molecular tumor characteristics define the…
SABCS 2021
MBC HR+: What is the best option after a CDK4/6i…
SABCS 2021
Integrating patients perspectives in metastatic breast…
TROPION-Tumor01
SABCS 2021
New ADCs on the horizon for TNBC patients
Keynote-355
SABCS 2021
Treatment options for patients with metastatic TNBC
EMERALD
SABCS 2021
Are SERDs a future therapy for endocrine resistant…
SUMMIT
SABCS 2021
Targeting rare mutations in breast cancer - is this the…
Destiny-Breast03
SABCS 2021
Therapy of brain metastasis – can T-DXd be the new SoC?
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!